ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1721

Development of User-Focused Standards of Care for Rheumatoid Arthritis the Www.Eumusc.Net Project – Work Package 5

Michaela Stoffer1, Josef S. Smolen2, Anthony D. Woolf3, Tanja A. Stamm4 and EUMUSC.net working group WP 55, 1Internal Medicine III, division of rheumatology, Medical University of Vienna, Vienna, Austria, 2Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 3Rheumatology Dept, Royal Cornwall Hospital, Truro Cornwall, United Kingdom, 4Rheumatology, Medical University of Vienna, Vienna, Austria, 5Royal Cornwall Hospital Treliske, Truro Cornwall, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Access to care, Education, patient and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Care of Patients With Rheumatoid Arthritis

Session Type: Abstract Submissions (ARHP)

Background/Purpose: The EUMUSC.net project facilitates cooperation between EU Member States and promotes a comprehensive European strategy to optimise musculoskeletal health.

The purpose of Work package 5, as a part of the EUMUSC.net project, was to develop evidence based and user-focused standards of care (SOC), for Rheumatoid Arthritis (RA).

Methods: A systematic review of international documents covering SOC for RA was conducted. National scientific societies, social leagues and health professional associations were contacted via the EULAR secretariat and asked to provide relevant documents. Documents concerning pharmacological and non-pharmacological interventions published after 2002 were included.

The obtained documents were evaluated based on the AGREE II criteria (www.agreetrust.org). All recommended methods to treat RA were extracted, as well as information on them and all recommendations given. Each of these methods was discussed in a consensus group meeting of 21 EUMUSC.net researchers and patient representatives from different countries regarding priority and relevance in their home countries as well as possible interrelation with other methods. A scheme was developed with groups of interventions and formulated in a way that could be understood by users. To this end, conventional DMARDs, biological agents, NSAIDs, were grouped under pharmacological treatment. Giving up smoking, weight control and physical activity were grouped under Lifestyle Interventions.

Results: 49 types of therapies or other interventions, such as DMARDs, biological agents, exercise based-, activity based interventions, were extracted from the documents and could be grouped into seven types of interventions, namely Pharmacological Treatment, Monitoring, Lifestyle Interventions, Surgery, Education/ Information/ Self Management, Non- Pharmacological Treatment and Access to care.

From these data 16 user-focused standards of care were formulated.

Conclusion: The lay version of the user-focused SOC will be available in all 23 official languages of the European Union for the information of people with RA across all member states. This work should contribute to the harmonization of RA treatment in Europe.


Disclosure:

M. Stoffer,
None;

J. S. Smolen,

Abbott Immunology Pharmaceuticals, Roche, MSD, Pfizer, UCB, BMS,

2,

Abbott Immunology Pharmaceuticals, Roche, MSD, Pfizer, UCB, BMS, Novo-Nordisk, Lilly, Atsra-Zeneca, Glaxo, Dandoz, Sanofi, Medimmune,

5,

Abbott Immunology Pharmaceuticals, Roche, MSD, Pfizer, UCB, BMS,

,

Rheumatology 5E,

;

A. D. Woolf,
None;

T. A. Stamm,

Abbott Immunology Pharmaceuticals,

5;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-user-focused-standards-of-care-for-rheumatoid-arthritis-the-www-eumusc-net-project-work-package-5/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology